ZURA$6.62
$6.40
Chart
Performance
Key Stats
AI ZURA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyZura Bio Limited presents a speculative but potentially rewarding investment opportunity within the biotechnology sector. Strong thematic alignment with immune and inflammatory disorder treatments, coupled with a solid clinical pipeline, supports a positive outlook. However, early-stage clinical development carries inherent risks, and the company currently lacks revenue and profitability, necessitating a careful, risk-adjusted approach.
Thematic
Zura Bio's focus on immune and inflammatory disorders aligns with significant growth trends in healthcare, driven by an aging population and increasing prevalence of chronic inflammatory conditions.
Fundamental
Zura Bio is a pre-revenue company with negative earnings and cash flow from operations. Its financial health relies on cash reserves and potential future financing. The current valuation, while not directly comparable due to lack of revenue, reflects the speculative nature of clinical-stage biotech.
Technical
The stock has experienced significant volatility, trading within a wide range over the past year. Recent price action suggests a potential consolidation phase. Short-term indicators show mixed signals, indicating a neutral stance without strong trending momentum.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 90 |
| Clinical Development Stage | 80 |
| Market Trends | 95 |
| Research & Development | 85 |
| Competitive Landscape | 75 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 50 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 40 |
| Moving Averages | 55 |
| Volume | 60 |
| Support/Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Cash Position
The company ended the latest quarter with $176.5 million in cash and cash equivalents, providing a substantial buffer for operations and potential investments.
Positive Equity Position
Total equity stands at $160 million, indicating a healthy balance sheet with assets significantly exceeding liabilities.
Bearish Points (8)
No Revenue Generation
The company currently has zero reported revenue, which is typical for pre-commercial biotechnology firms but presents a significant risk until products are approved and marketed.
Consistent Net Losses
The company has reported significant net losses in all provided periods (e.g., -$52.4 million in 2024, -$60.4 million in 2023), indicating a substantial cash burn rate.
Calendar
August 2025
13
Next Earnings Date
H: $
A: $
L: $
Profile
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Seasonals
Price Target
13.67 USD
The 39 analysts offering 1 year price forecasts for ZURA have a max estimate of 26.00 and a min estimate of 3.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Dominant global leader in autoimmune and inflammatory diseases, with blockbuster drugs like Humira, Skyrizi, and Rinvoq. Direct and indirect competition across multiple indications.
Weight: 96
Clinical-stage biotech developing izokibep, a direct IL-17A inhibitor for inflammatory diseases, representing direct competition with ZURA's lead candidate's mechanism of action.
Weight: 95
Strong presence in immunology with Taltz (ixekizumab), an IL-17A inhibitor, directly competing in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Also has Olumiant (JAK inhibitor).
Weight: 95
Global pharmaceutical leader with Cosentyx (secukinumab), another key IL-17A inhibitor, highly competitive in psoriasis, psoriatic arthritis, ankylosing spondylitis, and IBD.